Mouse Anti-MSMB Recombinant Antibody (CBFYM-2653) (CBMAB-M2842-FY)

Name: Mouse Anti-MSMB Recombinant Antibody (CBFYM-2653)
SKU: CBMAB-M2842-FY
Rating: 5 (1 reviews)

See all MSMB antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBFYM-2653

Application

WB, ICC, IHC-P, IHC-Fr, ELISA

Immunogen

Microseminoprotein Beta

Specificity

Human

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, pH 7.4, 50% glycerol

Preservative

0.02% Sodium azide

Concentration

0.5 mg/mL

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

microseminoprotein, beta-

Introduction

The protein encoded by this gene is a member of the immunoglobulin binding factor family. It is synthesized by the epithelial cells of the prostate gland and secreted into the seminal plasma. This protein has inhibin-like activity. It may have a role as an autocrine paracrine factor in uterine, breast and other female reproductive tissues. The expression of the encoded protein is found to be decreased in prostate cancer. Two alternatively spliced transcript variants encoding different isoforms are described for this gene. The use of alternate polyadenylation sites has been found for this gene.

Entrez Gene ID

4477

UniProt ID

P08118

Alternative Names

Microseminoprotein Beta; Prostate Secretory Protein Of 94 Amino Acids; Prostate Secreted Seminal Plasma Protein; Seminal Plasma Beta-Inhibin; Beta-Microseminoprotein; PSP-94; PSP94; IGBF; PN44; Immunoglobulin Binding Factor

Cellular Location

Secreted
Note: Sperm surface.

Involvement in disease

Prostate cancer, hereditary, 13 (HPC13):
A condition associated with familial predisposition to cancer of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.

Darayee, M., Geramizadeh, B., Tabei, S. M. B., Rezvani, A., Soleimanian, S., & Rahimi, A. (2022). Suggesting Tissue-Specific MSMB Gene Promoter as a Novel Approach for Prostate Targeted Gene Therapy. Asian Pacific Journal of Cancer Prevention: APJCP, 23(6), 1993.

Coste, F., Moreau, T., Labas, V., Chessé, M., Bregeon, M., Meudal, H., ... & Réhault‐Godbert, S. (2021). Three‐dimensional structures of avian beta‐microseminoproteins: insight from the chicken egg‐specific beta‐microseminoprotein 3 paralog. FEBS Open bio, 11(6), 1739-1756.

Wang, C., Qi, X., Zhou, X., Sun, J., Cai, D., Lu, G., ... & Zhao, H. (2020). RNA‐Seq analysis on ets1 mutant embryos of Xenopus tropicalis identifies microseminoprotein beta gene 3 as an essential regulator of neural crest migration. The FASEB Journal, 34(9), 12726-12738.

Shrivastava, P., Garg, H., Bhat, M., Dinda, A., & Kumar, R. (2020). Urinary prostate-specific antigen and microseminoprotein-beta levels in men with and without prostate cancer: A prospective cohort study. Indian Journal of Urology: IJU: Journal of the Urological Society of India, 36(1), 50.

Tumova, L., Zigo, M., Sutovsky, P., Sedmikova, M., & Postlerova, P. (2020). The ubiquitin-proteasome system does not regulate the degradation of porcine β-microseminoprotein during sperm capacitation. International Journal of Molecular Sciences, 21(11), 4151.

Bicak, M., Wang, X., Gao, X., Xu, X., Väänänen, R. M., Taimen, P., ... & Klein, R. J. (2020). Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB. Human molecular genetics, 29(10), 1581-1591.

Byrne, K. S., Appleby, P. N., Key, T. J., Holmes, M. V., Fensom, G. K., Agudo, A., ... & PRACTICAL Consortium. (2019). The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case–control and Mendelian randomization study in the European prospective investigation into cancer and nutrition. Annals of Oncology, 30(6), 983-989.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-MSMB Recombinant Antibody (CBFYM-2653)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-MSMB Recombinant Antibody (3B11) (CAT#: CBMAB-A5625-LY)

Mouse Anti-MSMB Recombinant Antibody (CBFYM-0737) (CAT#: CBMAB-M0879-FY)

Mouse Anti-MSMB Recombinant Antibody (YPSP-1) (CAT#: CBMAB-P0513-YC)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry